Virax Biolabs Group Ltd SEC filings VRAX
Virax Biolabs Group Ltd has 159 filings in SEC EDGAR's recent list, going back to Dec 27, 2021. Its latest annual report, Form 20-F, was filed on Jul 6, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | Jul 6, 2026 | Mar 31, 2026 |
| 20-F | Annual report (foreign issuer) | Jul 2, 2025 | Mar 31, 2025 |
| 20-F | Annual report (foreign issuer) | Aug 20, 2024 | Mar 31, 2024 |
| 20-F | Annual report (foreign issuer) | Jun 14, 2023 | Mar 31, 2023 |
| 20-F | Annual report (foreign issuer) | Aug 12, 2022 | Mar 31, 2022 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.